作者
Garyphallia Poulakou, Evangelos Dimakakos, Anastasios Kollias, Konstantinos G Kyriakoulis, Vasiliki Rapti, Ioannis Trontzas, Charalampos Thanos, Mahmoud Abdelrasoul, Theodora Vantana, Konstantinos Leontis, Eleni Kakalou, Katerina Argyraki, Ioannis Baraboutis, Evangelos Michelakis, Evangelos Giamarellos-Bourboulis, Katerina Dimakou, Georgios Tsoukalas, Angeliki Rapti, Evangelos D Michelakis, Konstantinos N Syrigos
发表日期
2021/1/1
期刊
in vivo
卷号
35
期号
1
页码范围
653-661
出版商
International Institute of Anticancer Research
简介
Background/Aim
To investigate the efficacy (prognosis, coagulation/inflammation biomarkers) and safety (bleeding events) of different anticoagulation dosages in COVID-19 inpatients. Patients and Methods
COVID-19 inpatients (Athens, Greece) were included. The “Enhanced dose THRomboprophylaxis in Admissions (ETHRA)” protocol was applied in certain Departments, suggesting the use of intermediate anticoagulation dosage. The primary endpoint was a composite of intubation/venous thromboembolism/death. Inflammation/coagulation parameters were assessed. Results
Among 127 admissions, 95 fulfilled the inclusion criteria. Twenty-one events (4 deaths, 17 intubations) were observed. Regression analysis demonstrated significant reduction of events with intermediate or therapeutic dosage [HR=0.16 (95%CI=0.05-0.52) p=0.002; HR=0.17 (0.04-0.71) p=0.015, respectively]. D-Dimer values were higher …学术搜索中的文章
G Poulakou, E Dimakakos, A Kollias, KG Kyriakoulis… - in vivo, 2021